COVID Conference News Virology Infectious Diseases Viruses

Respiratory  Virsues: new Frontiers Conference June 29-July 2, 2022

Respiratory viruses are particularly easy to contract compared to other viruses, and cause significant morbidity and mortality worldwide. Despite many decades of study, our ability to prevent and treat these infections is limited, as demonstrated by the recent COVID-19 pandemic. 

This Keystone Symposia conference on "Respiratory Viruses: New Frontiers" in Keystone, Colorado, will bring together researchers studying different respiratory viruses from both host and pathogen perspectives, to reveal novel cross-disciplinary insights into respiratory virus biology that will drive innovative strategies for prevention and treatment. The program will cover diverse approaches, tools and technologies that are advancing the field, as well as emerging research on host-virus interactions, long-term ramifications of respiratory infections and recent clinical successes and failures. 

1920x1080_2022J4-KSRespiratoryVirus22 (1)

As a joint meeting with the Keystone Symposia on “Viral Immunity,” all attendees will gain access to both meetings and joint sessions to promote collaborative synergy between virologists and immunologists towards clinical advances. 

Program Highlights: 

  • New Approaches to Studying Respiratory Viruses 
  • Zoonoses and Transmission 
  • Beyond Acute Disease: Consequences of Respiratory Virus Infections 
  • Prevention and Treatment Strategies: Vaccines and Antivirals 
  • Immunity and Respiratory Viruses: Good and Bad (joint session) 
  • Translational and Developmental Aspects of Antibodies (joint session) 

Register Now






Shannon Weiman
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.